Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRTCNASDAQ:SLNNASDAQ:SNDLNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRTCPureTech Health$19.25-0.5%$18.25$16.30▼$34.00$462.37M1.253,891 shs1,854 shsSLNSilence Therapeutics$2.77-19.5%$4.64$2.76▼$24.38$83.03M1.08282,870 shs210,551 shsSNDLSNDL$1.43-1.7%$1.68$1.37▼$2.93$374.46M3.391.94 million shs1.21 million shsUPBUpstream Bio$6.18-10.0%$8.63$5.01▼$29.46$332.57MN/A326,653 shs181,064 shsThe 10 Best Stocks to Own: Spring 2025Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRTCPureTech Health0.00%+11.46%+4.20%+1.90%-32.14%SLNSilence Therapeutics0.00%-3.37%-23.56%-50.22%-84.07%SNDLSNDL0.00%-8.23%-9.94%-16.67%-27.68%UPBUpstream Bio0.00%-9.84%-13.37%-59.87%+686,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPRTCPureTech Health1.5158 of 5 stars3.81.00.00.02.70.00.0SLNSilence Therapeutics2.0755 of 5 stars3.42.00.00.02.31.70.6SNDLSNDL3.6847 of 5 stars3.55.00.00.03.00.01.3UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRTCPureTech Health 3.50Strong Buy$45.00133.77% UpsideSLNSilence Therapeutics 2.71Moderate Buy$40.671,368.11% UpsideSNDLSNDL 3.00Buy$3.63154.39% UpsideUPBUpstream Bio 3.00Buy$56.50813.80% UpsideCurrent Analyst Ratings BreakdownLatest SLN, SNDL, PRTC, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.003/7/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/5/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.003/4/2025SLNSilence TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.003/4/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$6.00 ➝ $4.002/11/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.001/29/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRTCPureTech Health$3.33M138.85N/AN/A$16.94 per share1.14SLNSilence Therapeutics$43.26M1.92N/AN/A$0.71 per share3.90SNDLSNDL$920.45M0.41N/AN/A$3.47 per share0.41UPBUpstream Bio$2.37M139.94N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRTCPureTech Health-$65.70MN/A0.00N/AN/AN/AN/AN/A4/23/2025 (Estimated)SLNSilence Therapeutics-$53.82M-$0.95N/AN/AN/A-342.00%-62.81%-33.89%5/15/2025 (Estimated)SNDLSNDL-$127.91M-$0.26N/AN/AN/A-12.11%-8.27%-6.96%5/14/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest SLN, SNDL, PRTC, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPRTCPureTech HealthN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRTCPureTech HealthN/A3.68N/ASLNSilence TherapeuticsN/A9.319.31SNDLSNDL0.105.614.16UPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRTCPureTech Health0.04%SLNSilence Therapeutics98.73%SNDLSNDLN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipPRTCPureTech Health5.30%SLNSilence Therapeutics2.95%SNDLSNDLN/AUPBUpstream BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRTCPureTech Health10024.02 million22.67 millionNot OptionableSLNSilence Therapeutics10029.93 millionN/ANot OptionableSNDLSNDL580262.78 millionN/AOptionableUPBUpstream Bio3853.64 millionN/AN/ASLN, SNDL, PRTC, and UPB HeadlinesRecent News About These CompaniesCharles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB)March 30 at 3:08 AM | marketbeat.comBank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB)March 27, 2025 | marketbeat.comUpstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial ExecutionMarch 19, 2025 | tipranks.comUpstream Bio (NASDAQ:UPB) Stock Price Down 7.3% - Time to Sell?March 19, 2025 | marketbeat.comWilliam Blair Forecasts Increased Earnings for Upstream BioMarch 15, 2025 | marketbeat.comUpstream Bio’s Financial Results and Strategic ProgressMarch 13, 2025 | tipranks.comPromising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc.March 12, 2025 | tipranks.comUpstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPOMarch 12, 2025 | quiverquant.comUpstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 12, 2025 | globenewswire.comUPB Upstream Bio, Inc.March 8, 2025 | seekingalpha.comPiper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)March 4, 2025 | markets.businessinsider.comUpstream Bio to Present at Upcoming March Investor ConferencesFebruary 25, 2025 | globenewswire.comUpstream Bio, Inc. (UPB)January 25, 2025 | ca.finance.yahoo.comGlobal Upstream Bioprocessing Equipment Market Set to Soar, Projected to Reach USD 26.08 Billion by 2032January 6, 2025 | fmiblog.comUpstream Bio appoints GCDecember 27, 2024 | complianceweek.comNewly Public Biotech Startup Hires Life Sciences Veteran as GCDecember 17, 2024 | law.comUpstream Bio Appoints Allison Ambrose as General CounselDecember 17, 2024 | markets.businessinsider.comUpstream Bio to join Russell 2000 indexDecember 16, 2024 | msn.comUpstream Bio: Treating Respiratory Disorders With TSLP Targeting DifferentiationDecember 16, 2024 | seekingalpha.comUpstream Bio, Inc. to Join Russell 2000® Index Effective December 23, 2024December 16, 2024 | quiverquant.comUpstream Bio Announces Addition to Russell 2000® IndexDecember 16, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLN, SNDL, PRTC, and UPB Company DescriptionsPureTech Health NASDAQ:PRTC$19.25 -0.09 (-0.47%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Silence Therapeutics NASDAQ:SLN$2.77 -0.67 (-19.48%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.SNDL NASDAQ:SNDL$1.42 -0.03 (-1.72%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Upstream Bio NASDAQ:UPB$6.18 -0.69 (-10.00%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
